RSLS (reshapelifesciences.com) צמיחת רווח נקי למניה השנה

ReShape Lifesciences develops high-tech devices and gastric bands to address metabolic health. The annual net income per share growth history demonstrates real revenue dynamics, where 0.00 becomes the new value for this metric. The company attracts talent with generous bonuses for promoting wellness innovations, yet management operates in austerity mode, attempting to ensure the survival of the micro-cap business.

High margins on consumables for obesity treatment should translate into sustainable earnings per share growth for ReShape Lifesciences (RSLS). This indicator measures the percentage deviation of current net earnings per share from the same value last year, revealing the actual capitalization trend. By analyzing the rate of change in earnings per share over 12 months, an investor distinguishes fundamental business growth from speculative asset inflation.